Live feed07:00:00·947dPRReleasevia QuantisnowImmatics Reports Interim Clinical Data from ACTengine® IMA203 and IMA203CD8 TCR-T Monotherapies Targeting PRAME in an Ongoing Phase 1 TrialByQuantisnow·Wall Street's wire, on your screen.IMTX· Immatics N.V.Health Care
